On November 10, according to the official website of NMPA,Qilu PharmaceuticalDeclaredEntacapone and Levodopa Tablets (Ⅱ)Approved for marketing and deemed to have passed the evaluation, used for treating adult Parkinson's disease patients with "wearing-off" motor fluctuations that cannot be controlled by levodopa/DDC inhibitor therapy.

Screenshot source: NMPA

Entacapone and Levodopa Tablets (Ⅱ)Original Research byOrion PharmaCompany R&D.Entacapone and Levodopa TabletsIt was first approved by the FDA for marketing in 2003 for the treatment of Parkinson's disease. The Mox Entropy Pharma database shows,Entacapone and Levodopa Tablets (Ⅱ)The performance in the market has been particularly impressive. In the 2024 all-terminal hospital market in China, its sales approached 200 million yuan, with a year-on-year increase of 18.39%; by the first half of 2025, sales exceeded 120 million yuan, with a year-on-year growth rate reaching 41.11%, showing strong development momentum.

Screenshot source: Mosan Medicine All-Terminal Hospital Database

August 2024,Shijiazhuang SiyaoDeclaredEntacapone and Levodopa Tablets (Ⅱ)Approved for marketing, as the first domestic generic. Qilu Pharmaceutical launched in 2022.Entacapone and Levodopa Tablets (Ⅱ)TheResearch and Development. This time, Qilu Pharmaceutical Co., Ltd. has been approved for marketing.Entacapone and Levodopa Tablets (Ⅱ)The second in China, forming a competitive landscape of 1 original + 2 domestically produced.

Screenshot source: Mosentropy Medicine Approved Drug Summary Database

Since the beginning of this year,Qilu PharmaceuticalIn the field of drug research and development, it has achieved fruitful results, with 26 varieties approved and positively evaluated. Among them,Ixazomib Citrate Capsules, Ibrutinib Tablets, Etoposide Injection, Amisulpride Injection, Olanzapine for InjectionFive products have become the first in China to pass the evaluation, demonstrating their strong R&D strength and innovation capabilities.

This time,Entacapone and Levodopa Tablets (Ⅱ)The approval and market launch not only further enriches the company's product line and enhances market competitiveness, but also will further meet clinical needs, providing a new treatment option for patients with Parkinson's disease.

END

This article is original. Please leave a message to obtain authorization for reprint.

Recent Popular Resource Acquisition

Trends in Clinical Trials in China and the Outlook for International Multicenter Clinical Trials - 202505

2024 Pharmaceutical Enterprise Comprehensive Strength Ranking - 202505

Analysis Report on China's Herpes Zoster Vaccine Industry - 202505

China Pharmaceutical Analysis Report 2023H2-2024H1 - 202504

Data Insights: Application, Approval, and Sales of Innovative Traditional Chinese Medicine, Classic Prescriptions, Improved New Drugs, and Same-name Same-formula Products - 202503

2024 China Class 1 New Drug Targets White Paper - 202503

Top 100 List of Innovative Development of China's AI Medical and Health Enterprises - 202502

Decoding Skincare Anti-Aging: Consumer Preference Insights and Market Landscape Analysis - 202502

Analysis Report on New Drugs Approved by the FDA for Marketing in 2024 - 202501

Small Molecule Drug White Paper (I) - 202501

2024 China Healthcare Investment and Financing Panorama Insights Report - 202501

2024 Medical Insurance Negotiation and Market Analysis Report - 202501

More RecentlyMoxie ConsultingPopular Report, Scan the QR Code Below to Claim

Contact us to experience more professional services from Mosen Pharma.
WillDiscussion CombineMade	GardenDistrict TakeWu	Database Consultation	Customization Service	Media Cooperation

ClickImage Above, you can start the Mosan Chemistry data query

ClickReadRead the Original Text, apply for a free trial of MosEntropy Pharma Enterprise Edition!